What’s New in the Treatment of Spinal Muscular Atrophy скачать в хорошем качестве

What’s New in the Treatment of Spinal Muscular Atrophy

In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes: • Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplam • Discussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complications • Review of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDA Presenters: Julie Parsons, MD Co-Director, Neuromuscular Clinic Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders Professor of Clinical Pediatrics and Neurology Children’s Hospital Colorado Denver, Colorado Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN Senior Director of Nursing, Palliative Care Psychosocial Oncology and Palliative Care Dana-Farber Cancer Institute Boston, Massachusetts Supported by an educational grant from Biogen Link to full program: bit.ly/41kw2dK (https://practicingclinicians.com/CE-C...) Link to CME: Claim credit - bit.ly/40fkDKD (https://www.practicingclinicians.com/...)   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.